MDT
Neutral signalScored 2026-10-21 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Research, not advice.
À propos
Medtronic Plc
- Nom
- Medtronic Plc
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NYSE
- Capitalisation
- $122.6B
- Employés
- 95,000
- PDG
- Geoffrey Straub Martha
- Site web
- https://www.medtronic.com
- Marché
- AVRBSXEWGNGBYLIVNPEN
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 50 000 titres (~4 750 000,00 $ US)
- Insiders
- Martha Geoffrey
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$5,889,203
Avg sell (VWAP, 90d window) $95.14 vs last close $94.79 (-0.4%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$5,750,320 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-15
- Liquidity
- Liquid $3,175,274,595/day · 20d vol
- Last synced
-
2026-10-26 21:10:40
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-15 | Marinaro Michael | Sell · S · 10b5-1 | 10,420 | $96.00 | $1,000,320 | Form 4 |
| 2026-10-15 | Martha Geoffrey | Sell · S · 10b5-1 | 50,000 | $95.00 | $4,750,000 | Form 4 |
| 2026-09-16 | KIIL HARRY SKIP | Sell · S | 1,483 | $93.65 | $138,883 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-09-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-08-24 | Kevin Hern | Sale (Full) | $15,001 - $50,000 |
| 2026-07-30 | Rich McCormick | Sale | $1,001 - $15,000 |
| 2026-05-15 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2026-03-20 | Kevin Hern | Sale (Full) | $15,001 - $50,000 |
| 2025-12-18 | Julie Johnson | Sale (Full) | $1,001 - $15,000 |
| 2025-11-13 | Julie Johnson | Sale (Partial) | $1,001 - $15,000 |
| 2025-11-05 | Rich McCormick | Purchase | $1,001 - $15,000 |
| 2025-08-14 | Julie Johnson | Sale (Partial) | $1,001 - $15,000 |
| 2025-06-27 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-05-15 | Robert P. Bresnahan | Purchase | $1,001 - $15,000 |
| 2025-05-08 | Jefferson Shreve | Sale (Full) | $15,001 - $50,000 |
| 2025-05-07 | Julie Johnson | Sale (Partial) | $1,001 - $15,000 |
| 2025-04-08 | Robert P. Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-03-24 | George Whitesides | Sale (Full) | $50,001 - $100,000 |
| 2025-03-20 | Bruce Westerman | Sale (Full) | $1,001 - $15,000 |
| 2025-03-04 | Bruce Westerman | Purchase | $1,001 - $15,000 |
| 2025-02-25 | Robert P. Bresnahan | Purchase | $1,001 - $15,000 |
| 2025-01-06 | Emily Randall | Sale (Full) | $1,001 - $15,000 |
| 2024-11-15 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-09-04 | John James | Sale (Full) | $1,001 - $15,000 |
| 2024-07-09 | Earl Blumenauer | Sale (Full) | $1,001 - $15,000 |
| 2024-07-02 | Kathy E. Manning | Sale (Partial) | $1,001 - $15,000 |
| 2024-06-18 | John James | Purchase | $1,001 - $15,000 |
| 2024-06-03 | John James | Sale (Partial) | $1,001 - $15,000 |
| 2024-02-13 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-01-23 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2024-01-23 | Kathy E. Manning | Purchase | $15,001 - $50,000 |
| 2023-12-28 | Jared Moskowitz | Sale (Full) | $1,001 - $15,000 |
| 2023-12-28 | Jared Moskowitz | Sale (Full) | $1,001 - $15,000 |
| 2023-12-12 | Kathy E. Manning | Sale (Full) | $15,001 - $50,000 |
| 2023-12-12 | Kathy E. Manning | Sale | $1,001 - $15,000 |
| 2023-12-05 | Debbie Dingell | Purchase | $15,001 - $50,000 |
| 2023-11-10 | John James | Purchase | $1,001 - $15,000 |
| 2023-10-24 | Greg Stanton | Sale (Full) | $1,001 - $15,000 |
| 2023-10-10 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-10-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-26 | Greg Stanton | Purchase | $1,001 - $15,000 |
| 2023-09-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-08-07 | Michael Guest | Purchase | $1,001 - $15,000 |
| 2023-07-14 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2023-06-15 | Pete Sessions | Sale (Full) | $15,001 - $50,000 |
| 2023-05-23 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-04-28 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2023-04-28 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2023-03-24 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-03-15 | Rich McCormick | Purchase | $1,001 - $15,000 |
| 2023-03-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-03-06 | Daniel Goldman | Purchase | $15,001 - $50,000 |
| 2023-02-15 | Scott Franklin | Sale (Full) | $50,001 - $100,000 |
| 2023-02-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-02-10 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2023-01-31 | Daniel Goldman | Purchase | $15,001 - $50,000 |
| 2023-01-31 | Kevin Hern | Sale (Full) | $1,001 - $15,000 |
| 2023-01-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-01-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-21 | Bob Gibbs | Sale (Full) | $15,001 - $50,000 |
| 2022-12-06 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-12-06 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-11-08 | Kurt Schrader | Purchase | $1,001 - $15,000 |
| 2022-10-26 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2022-10-26 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2022-10-26 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2022-10-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-10-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-10-12 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2022-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-09-15 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-09-13 | Scott Franklin | Purchase | $15,001 - $50,000 |
| 2022-09-13 | Scott Franklin | Purchase | $1,001 - $15,000 |
| 2022-09-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-07-29 | Alan Lowenthal | Sale (Partial) | $1,001 - $15,000 |
| 2022-07-28 | Alan Lowenthal | Sale (Partial) | $1,001 - $15,000 |
| 2022-07-27 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2022-07-27 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2022-07-19 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-06-28 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-06-28 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-06-28 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-06-21 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-06-21 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-06-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-06-16 | Ro Khanna | Sale | $50,001 - $100,000 |
| 2022-06-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-06-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-06-08 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-05-05 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-04-22 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-04-21 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-04-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-04-13 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-04-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-03-29 | William R. Keating | Sale (Full) | $1,001 - $15,000 |
| 2022-03-16 | John Henry Rutherford | Sale (Full) | $1,001 - $15,000 |
| 2022-03-15 | Scott Franklin | Purchase | $15,001 - $50,000 |
| 2022-02-22 | Lois Frankel | Sale (Full) | $1,001 - $15,000 |
| 2022-02-18 | Earl Blumenauer | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-21 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Medtronic's solid liquidity (score 85) and stable fundamentals (score 65) are materially offset by a very weak catalyst score (15), driven by significant insider selling from the CEO and net congressional selling with…
The first sentence of the analysis written for MDT on 2026-10-21 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Supports a bullish reading. Current ratio 2.13 · operating margin 18%
Suggested stop 91.13, nearest stored support minus 0.5 ATR(3.9% under the last close). Reward/risk to the next stored resistance is 0.17. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-20 Arlington Financial Advisors LLC Acquires 9,743 Shares of Medtronic PLC $MDT Arlington Financial Advisors LLC bought a new position in Medtronic PLC (NYSE: MDT) during the third quarter, according to its most recent Form 13F filing with the SEC. The firm bought 9,743 shares of the medical technology company''s stock, valued at approximately $841,000. Several other institutional investors and hedge funds have also made
- 2026-10-19 Medtronic (MDT) Stock Dips While Market Gains: Key Facts In the latest trading session, Medtronic (MDT) closed at $92.77, marking a -2.09% move from the previous day.
- 2026-10-19 The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning Rate and energy headlines have kept the broad market jumpy, yet one sector keeps finding buyers. Healthcare has led on days when the S&P 500 slipped, and the Nasdaq Biotechnology Index has pushed to record highs.
- 2026-10-19 First Bank & Trust Buys 10,881 Shares of Medtronic PLC $MDT First Bank and Trust lifted its stake in shares of Medtronic PLC (NYSE: MDT) by 43.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 35,848 shares of the medical technology company''s stock after purchasing an additional 10,881 shares during the quarter.
- 2026-10-18 Medtronic (NYSE:MDT) Stock: Insider Geoffrey Martha Sells 50,000 Shares Medtronic PLC (NYSE: MDT - Get Free Report) CEO Geoffrey Martha sold 50,000 shares of the stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $95.00, for a total value of $4,750,000.00. Following the completion of the transaction, the chief executive officer owned 277,866 shares in
- 2026-10-17 How Many Shares Would It Take to Earn $1,000 a Year From This Future Dividend King? A recent spinoff could pave the way for greater dividend growth.
- 2026-10-16 Is it Apt to Retain Medtronic Stock in Your Portfolio Now? MDT expands in cardiac ablation, robotics, hypertension and digital surgery, but tariff, inflation and currency risks are likely to pressure margins.
- 2026-10-15 Medtronic Named to TIME Best Inventions of 2026 List for Stealth AXiS™ surgical system and Corsano™* multi-parameter wearable Annual list recognizes inventions making the world better and smarter GALWAY, Ireland, Oct. 15, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Stealth AXiS™ surgical system and the Corsano™* multi-parameter wearable have been named to the TIME Best Inventions of 2026 list. The annual award highlights the most impactful new products and ideas of the year, assessed by TIME editors.
- 2026-10-15 Procter & Gamble Has Raised Its Dividend for 70 Years. These 4 Stocks Also Reward Patience A dividend that keeps growing beats a fat yield that gets cut, but only if the company can actually afford to keep raising it.
- 2026-10-15 3 Overlooked Healthcare Dividend Stocks That Could Keep Paying for Decades Most income investors chase flashy yields and overlook the quiet compounders that have raised their dividends through recessions, rate shocks, and global pandemics.
Market snapshot
Financial ratios
| Metric | Trend | 2026-04-24 | 2025-04-25 | 2024-04-26 | 2023-04-28 | 2022-04-29 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 65.0% | 65.3% | 65.3% | 65.7% | 68.0% | |
| Ebit Margin | 18.8% | 19.0% | 17.2% | 19.2% | 19.2% | |
| Ebitda Margin | 27.0% | 27.5% | 25.3% | 27.9% | 27.7% | |
| Operating Profit Margin | 17.8% | 17.8% | 15.9% | 17.6% | 18.2% | |
| Pretax Profit Margin | 16.9% | 16.8% | 14.9% | 17.2% | 17.4% | |
| Continuous Operations Profit Margin | 13.3% | 14.0% | 11.4% | 12.1% | 16.0% | |
| Net Profit Margin | 13.2% | 13.9% | 11.4% | 12.0% | 15.9% | |
| Bottom Line Profit Margin | 13.2% | 13.9% | 11.4% | 12.0% | 15.9% | |
| Current Ratio | 2.126 | 1.849 | 2.033 | 2.395 | 1.860 | |
| Quick Ratio | 1.616 | 1.424 | 1.550 | 1.810 | 1.488 | |
| Solvency Ratio | 0.181 | 0.173 | 0.160 | 0.164 | 0.202 | |
| Cash Ratio | 0.167 | 0.172 | 0.119 | 0.170 | 0.300 | |
| Price To Earnings Ratio | 22.219 | 23.185 | 28.787 | 32.138 | 27.829 | |
| Price To Earnings Growth Ratio | 6.721 | 0.747 | -13.578 | -1.310 | 0.697 | |
| Forward Price To Earnings Growth Ratio | 6.721 | 0.747 | -13.578 | -1.310 | 0.697 | |
| Price To Earnings Diluted Ratio | 22.338 | 23.313 | 28.891 | 32.252 | 27.979 | |
| Price To Earnings Diluted Growth Ratio | 6.720 | 0.757 | -13.579 | -1.322 | 0.696 | |
| Price To Book Ratio | 2.159 | 2.253 | 2.108 | 2.349 | 2.666 | |
| Price To Sales Ratio | 2.937 | 3.226 | 3.271 | 3.873 | 4.421 | |
| Price To Free Cash Flow Ratio | 19.683 | 20.867 | 20.360 | 26.407 | 23.435 | |
| Price To Operating Cash Flow Ratio | 14.570 | 15.360 | 15.599 | 20.027 | 19.071 | |
| Debt To Assets Ratio | 0.301 | 0.311 | 0.278 | 0.268 | 0.265 | |
| Debt To Equity Ratio | 0.565 | 0.594 | 0.498 | 0.473 | 0.459 | |
| Debt To Capital Ratio | 0.361 | 0.373 | 0.333 | 0.321 | 0.315 | |
| Long Term Debt To Capital Ratio | 0.346 | 0.348 | 0.322 | 0.321 | 0.279 | |
| Financial Leverage Ratio | 1.881 | 1.909 | 1.792 | 1.767 | 1.731 | |
| Working Capital Turnover Ratio | 3.022 | 3.038 | 2.723 | 2.682 | 2.565 | |
| Operating Cash Flow Ratio | 0.629 | 0.547 | 0.629 | 0.667 | 0.593 | |
| Operating Cash Flow Sales Ratio | 0.202 | 0.210 | 0.210 | 0.193 | 0.232 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.740 | 0.736 | 0.766 | 0.758 | 0.814 | |
| Debt Service Coverage Ratio | 3.408 | 2.302 | 3.917 | 10.966 | 1.940 | |
| Interest Coverage Ratio | 9.045 | 8.169 | 7.154 | 8.624 | 10.401 | |
| Short Term Operating Cash Flow Coverage Ratio | 4.113 | 2.456 | 6.250 | 464.538 | 1.966 | |
| Operating Cash Flow Coverage Ratio | 0.262 | 0.247 | 0.271 | 0.248 | 0.305 | |
| Capital Expenditure Coverage Ratio | 3.850 | 3.789 | 4.277 | 4.139 | 5.370 | |
| Dividend Paid And Capex Coverage Ratio | 1.322 | 1.293 | 1.292 | 1.190 | 1.546 | |
| Dividend Payout Ratio | 0.758 | 0.770 | 0.997 | 0.962 | 0.671 | |
| Enterprise Value Multiple | 13.540 | 14.590 | 15.800 | 16.531 | 18.286 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 65.0% | ▼-0.3% | ▼-0.9% |
| Ebit Margin | 18.8% | ▼-0.1% | ▲0.2% |
| Ebitda Margin | 27.0% | ▼-0.5% | ▼-0.1% |
| Operating Profit Margin | 17.8% | ▲0.0% | ▲0.4% |
| Pretax Profit Margin | 16.9% | ▲0.1% | ▲0.2% |
| Continuous Operations Profit Margin | 13.3% | ▼-0.7% | ▼-0.1% |
| Net Profit Margin | 13.2% | ▼-0.7% | ▼-0.1% |
| Bottom Line Profit Margin | 13.2% | ▼-0.7% | ▼-0.1% |
| Current Ratio | 2.126 | ▲0.277 | ▲0.073 |
| Quick Ratio | 1.616 | ▲0.192 | ▲0.038 |
| Solvency Ratio | 0.181 | ▲0.007 | ▲0.004 |
| Cash Ratio | 0.167 | ▼-0.005 | ▼-0.018 |
| Price To Earnings Ratio | 22.219 | ▼-0.966 | ▼-4.613 |
| Price To Earnings Growth Ratio | 6.721 | ▲5.974 | ▲8.066 |
| Forward Price To Earnings Growth Ratio | 6.721 | ▲5.974 | ▲8.066 |
| Price To Earnings Diluted Ratio | 22.338 | ▼-0.975 | ▼-4.617 |
| Price To Earnings Diluted Growth Ratio | 6.720 | ▲5.963 | ▲8.066 |
| Price To Book Ratio | 2.159 | ▼-0.094 | ▼-0.148 |
| Price To Sales Ratio | 2.937 | ▼-0.289 | ▼-0.609 |
| Price To Free Cash Flow Ratio | 19.683 | ▼-1.184 | ▼-2.467 |
| Price To Operating Cash Flow Ratio | 14.570 | ▼-0.790 | ▼-2.355 |
| Debt To Assets Ratio | 0.301 | ▼-0.011 | ▲0.016 |
| Debt To Equity Ratio | 0.565 | ▼-0.029 | ▲0.047 |
| Debt To Capital Ratio | 0.361 | ▼-0.011 | ▲0.021 |
| Long Term Debt To Capital Ratio | 0.346 | ▼-0.002 | ▲0.023 |
| Financial Leverage Ratio | 1.881 | ▼-0.028 | ▲0.065 |
| Working Capital Turnover Ratio | 3.022 | ▼-0.015 | ▲0.216 |
| Operating Cash Flow Ratio | 0.629 | ▲0.082 | ▲0.016 |
| Operating Cash Flow Sales Ratio | 0.202 | ▼-0.009 | ▼-0.008 |
| Free Cash Flow Operating Cash Flow Ratio | 0.740 | ▲0.004 | ▼-0.023 |
| Debt Service Coverage Ratio | 3.408 | ▲1.106 | ▼-1.099 |
| Interest Coverage Ratio | 9.045 | ▲0.876 | ▲0.366 |
| Short Term Operating Cash Flow Coverage Ratio | 4.113 | ▲1.657 | ▼-91.751 |
| Operating Cash Flow Coverage Ratio | 0.262 | ▲0.015 | ▼-0.004 |
| Capital Expenditure Coverage Ratio | 3.850 | ▲0.061 | ▼-0.435 |
| Dividend Paid And Capex Coverage Ratio | 1.322 | ▲0.029 | ▼-0.006 |
| Dividend Payout Ratio | 0.758 | ▼-0.012 | ▼-0.074 |
| Enterprise Value Multiple | 13.540 | ▼-1.051 | ▼-2.210 |
Key metrics
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Market cap | $106.80B | $108.20B | $105.87B | $120.95B | $140.09B | |
| Enterprise value | $132.81B | $134.49B | $129.61B | $143.77B | $160.49B | |
| EV / Sales | 3.65x | 4.01x | 4.00x | 4.60x | 5.07x | |
| EV / Op. cash flow | 18.12x | 19.09x | 19.10x | 23.81x | 21.85x | |
| EV / Free cash flow | 24.48x | 25.94x | 24.93x | 31.39x | 26.85x | |
| EV / EBITDA | 13.54x | 14.59x | 15.80x | 16.53x | 18.29x | |
| Net debt / EBITDA | 2.65x | 2.85x | 2.89x | 2.62x | 2.32x | |
| Current ratio | 2.13x | 1.85x | 2.03x | 2.40x | 1.86x | |
| Income quality | 1.51x | 1.50x | 1.85x | 1.60x | 1.45x | |
| Graham number | $57 | $55 | $49 | $50 | $58 | |
| Graham net-net | -$20 | -$21 | -$18 | -$18 | -$16 | |
| Tax burden | 78.2% | 82.8% | 76.0% | 70.1% | 91.3% | |
| Interest burden | 89.6% | 88.5% | 87.1% | 89.4% | 90.9% | |
| Working capital | $13.13B | $10.94B | $11.15B | $12.62B | $10.66B | |
| Invested capital | $73.28B | $71.18B | $71.49B | $74.46B | $72.17B | |
| Return on assets | 5.2% | 5.1% | 4.1% | 4.1% | 5.5% | |
| Operating ROA | 7.0% | 6.6% | 5.7% | 6.0% | 6.3% | |
| Return on tangible assets | 11.9% | 12.2% | 10.3% | 10.8% | 14.4% | |
| Return on equity | 9.7% | 9.7% | 7.3% | 7.3% | 9.6% | |
| Return on invested capital | 6.1% | 6.1% | 4.9% | 4.7% | 6.4% | |
| Return on capital employed | 7.9% | 7.6% | 6.5% | 6.7% | 7.3% | |
| Earnings yield | 4.5% | 4.3% | 3.5% | 3.1% | 3.6% | |
| Free cash flow yield | 5.1% | 4.8% | 4.9% | 3.8% | 4.3% | |
| Capex / Op. cash flow | 26.0% | 26.4% | 23.4% | 24.2% | 18.6% | |
| Capex / Depreciation | 64.4% | 65.0% | 60.0% | 54.1% | 50.5% | |
| Capex / Sales | 5.2% | 5.5% | 4.9% | 4.7% | 4.3% | |
| SG&A / Sales | 32.4% | 32.3% | 33.2% | 33.4% | 32.5% | |
| R&D / Sales | 7.9% | 8.1% | 8.5% | 8.6% | 8.7% | |
| Stock comp / Sales | 1.3% | 1.3% | 1.2% | 1.1% | 1.1% | |
| Intangibles / Total assets | 56.7% | 58.3% | 60.2% | 61.9% | 61.7% | |
| Days sales outstanding | 67d | 71d | 69d | 70d | 64d | |
| Days payables outstanding | 76d | 77d | 78d | 91d | 82d | |
| Operating cycle | 237d | 243d | 239d | 250d | 230d | |
| Cash conversion cycle | 162d | 166d | 160d | 160d | 148d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years